<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-a24a30964bd64d43ba737b23f61c6bf2779f4f2eb28300b43b1667de4dd738de">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=6&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=6&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-28T15:19:00Z" timezone="America/New_York" class="datetime">Jun 28, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/health-canada-approves-prsymdekotm-tezacaftorivacaftor-and" hreflang="en">Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/health-canada-approves-prsymdekotm-tezacaftorivacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25241/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-21T19:25:00Z" timezone="America/New_York" class="datetime">Jun 21, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertexs-paul-negulescu-awarded-warren-alpert-foundation-prize" hreflang="en">Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertexs-paul-negulescu-awarded-warren-alpert-foundation-prize" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25221/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-18T17:00:00Z" timezone="America/New_York" class="datetime">Jun 18, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-opens-expanded-research-site-san-diego" hreflang="en">Vertex Opens Expanded Research Site in San Diego</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company’s research presence in the area, and
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-opens-expanded-research-site-san-diego" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25216/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-18T11:00:00Z" timezone="America/New_York" class="datetime">Jun 18, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-long-term-access-agreement-sweden-cystic" hreflang="en">Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-long-term-access-agreement-sweden-cystic" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25211/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-14T13:30:00Z" timezone="America/New_York" class="datetime">Jun 14, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-foundation-and-employees-donate-1-million-through" hreflang="en">The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-foundation-and-employees-donate-1-million-through" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25206/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-07T08:30:00Z" timezone="America/New_York" class="datetime">Jun 7, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-data-presented-european-cystic-fibrosis-society-ecfs" hreflang="en">Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Data from KALYDECO ® (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-data-presented-european-cystic-fibrosis-society-ecfs" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25201/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-06-06T20:01:00Z" timezone="America/New_York" class="datetime">Jun 6, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13-0" hreflang="en">Vertex to Present at the Goldman Sachs Healthcare Conference on June 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management’s remarks will be
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25191/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-05-30T20:45:00Z" timezone="America/New_York" class="datetime">May 30, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-provide-update-fda-review" hreflang="en">CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-provide-update-fda-review" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25146/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-05-01T12:30:00Z" timezone="America/New_York" class="datetime">May 1, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-awards-400000-scholarships-people-living-cystic-fibrosis" hreflang="en">Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  All in for CF Scholarship Program Doubles to Help 80 Recipients Pursue Higher Education BOSTON --(BUSINESS WIRE)--May 1, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-awards-400000-scholarships-people-living-cystic-fibrosis" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25091/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-04-26T20:05:00Z" timezone="America/New_York" class="datetime">Apr 26, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2018-financial-results" hreflang="en">Vertex Reports First-Quarter 2018 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&amp;amp;D and SG&amp;amp;A expense guidance of $1.50 to $1.55
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2018-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25061/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-04-26T20:01:00Z" timezone="America/New_York" class="datetime">Apr 26, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-initiates-phase-3-studies-vx-445-tezacaftor-and-ivacaftor" hreflang="en">Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New Drug Application based on 4-week
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-initiates-phase-3-studies-vx-445-tezacaftor-and-ivacaftor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25056/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-04-17T20:01:00Z" timezone="America/New_York" class="datetime">Apr 17, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2018-financial-results-april-26" hreflang="en">Vertex to Announce First Quarter 2018 Financial Results on April 26</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 17, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2018-financial-results-april-26" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25021/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-03-29T18:18:00Z" timezone="America/New_York" class="datetime">Mar 29, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief" hreflang="en">Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Mar. 29, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/24976/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-03-29T18:18:00Z" timezone="America/New_York" class="datetime">Mar 29, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief-0" hreflang="en">Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief-0" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e9d3c729-b681-422f-a038-a5a9b034b65f" type="application/pdf" title="VRTX_News_2018_3_29_General_Business.pdf">Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer</a></span><span class="filesize"> 13.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-03-12T20:01:00Z" timezone="America/New_York" class="datetime">Mar 12, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-cowen-healthcare-conference-march-13" hreflang="en">Vertex to Present at the Cowen Healthcare Conference on March 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET . The audio portion of management&#039;s remarks will be available live through Vertex&#039;s website,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-cowen-healthcare-conference-march-13" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/9f08603e-a7b5-494d-9eca-7ba1c0fd6f5d" type="application/pdf" title="VRTX_News_2018_3_12_Webcasts.pdf">Vertex to Present at the Cowen Healthcare Conference on March 13</a></span><span class="filesize"> 11 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-03-01T12:30:00Z" timezone="America/New_York" class="datetime">Mar 1, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-initiates-phase-3-study-vx-659-tezacaftor-and-ivacaftor" hreflang="en">Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV 1 &amp;nbsp;of 9.7 percentage points when VX-659 was added in people with CF who have two F508del mutations who were already receiving
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-initiates-phase-3-study-vx-659-tezacaftor-and-ivacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/106f6240-f36a-41e7-9529-6b25a2637fcd" type="application/pdf" title="VRTX_News_2018_3_1_General_Business.pdf">Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 28.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-02-26T14:15:00Z" timezone="America/New_York" class="datetime">Feb 26, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-reshma-kewalramani-md-chief-medical-officer" hreflang="en">Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4041&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Other</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-reshma-kewalramani-md-chief-medical-officer" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e49bac3a-0c7b-43d7-92fd-4b8f7effd59b" type="application/pdf" title="VRTX_News_2018_2_26_Other.pdf">Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer</a></span><span class="filesize"> 15.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-02-21T21:01:00Z" timezone="America/New_York" class="datetime">Feb 21, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-initiates-first-phase-3-study-vx-659-tezacaftor-and" hreflang="en">Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Global Phase 3 study to enroll 360 patients with one F508del mutation and one minimal function mutation- -Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-initiates-first-phase-3-study-vx-659-tezacaftor-and" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e136394a-d5a2-4db2-afe0-054b3d65f064" type="application/pdf" title="VRTX_News_2018_2_21_General_Business.pdf">Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis</a></span><span class="filesize"> 21.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-02-14T13:30:00Z" timezone="America/New_York" class="datetime">Feb 14, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-treatment-nav18-inhibitor-vx-150-showed" hreflang="en">Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute pain is the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-treatment-nav18-inhibitor-vx-150-showed" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/f738a6d4-4bf6-4974-82e0-71b1498be02a" type="application/pdf" title="VRTX_News_2018_2_14_General_Business.pdf">Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study</a></span><span class="filesize"> 88.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-02-12T21:50:00Z" timezone="America/New_York" class="datetime">Feb 12, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-symdekotm-tezacaftorivacaftor-and-ivacaftor-treat" hreflang="en">FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - SYMDEKO is Vertex&#039;s third medicine to treat the underlying cause of CF - - SYMDEKO to begin shipping to pharmacies this week - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO ™
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-symdekotm-tezacaftorivacaftor-and-ivacaftor-treat" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/aa8947ae-56ea-41a3-998a-33a3d60bc437" type="application/pdf" title="VRTX_News_2018_2_12_General_Business.pdf">FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene</a></span><span class="filesize"> 102.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-02-01T05:05:00Z" timezone="America/New_York" class="datetime">Feb 1, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-selects-two-next-generation-correctors-vx-659-and-vx-445" hreflang="en">Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Phase 2 data showed mean absolute improvements in ppFEV 1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445, respectively, in triple combination with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation (F508del/Min); triple
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-selects-two-next-generation-correctors-vx-659-and-vx-445" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/201507c2-afe0-4616-980b-d4492e1daad8" type="application/pdf" title="VRTX_News_2018_2_1_General_Business.pdf">Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis</a></span><span class="filesize"> 35.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-01-31T21:05:00Z" timezone="America/New_York" class="datetime">Jan 31, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2017-financial" hreflang="en">Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2017-financial" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/317de5f1-650d-4193-887b-dbf6216c57b1" type="application/pdf" title="VRTX_News_2018_1_31_Financial_Results.pdf">Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results</a></span><span class="filesize"> 183.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-01-10T09:00:00Z" timezone="America/New_York" class="datetime">Jan 10, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-eu-approval-orkambir-lumacaftorivacaftor" hreflang="en">Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - - Existing reimbursement agreements in countries like Ireland will enable rapid access to ORKAMBI; country-by-country reimbursement processes will now begin in other countries- LONDON
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-eu-approval-orkambir-lumacaftorivacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d8eabce7-bed8-4fb0-bfd5-ee00e28ae2b2" type="application/pdf" title="VRTX_News_2018_1_10_General_Business.pdf">Vertex Receives EU Approval for ORKAMBI&#174; (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation</a></span><span class="filesize"> 20.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-01-03T21:01:00Z" timezone="America/New_York" class="datetime">Jan 3, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare-2" hreflang="en">Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET ( 9:30 a.m. PT ). The audio portion of management&#039;s remarks can be accessed live through
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare-2" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0b23df60-f462-41a5-8e82-684a55bd7a63" type="application/pdf" title="VRTX_News_2018_1_3_Webcasts.pdf">Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results</a></span><span class="filesize"> 10.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-12-12T13:30:00Z" timezone="America/New_York" class="datetime">Dec 12, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-co-develop-and-co-commercialize" hreflang="en">Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics - -Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in β-thalassemia in 2018- -Preclinical data for CTX001 presented
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-co-develop-and-co-commercialize" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/88e35af3-4d9e-4b24-b6c7-ff3c397bc6d5" type="application/pdf" title="VRTX_News_2017_12_12_General_Business.pdf">Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and &#946;-Thalassemia</a></span><span class="filesize"> 175.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-12-07T13:00:00Z" timezone="America/New_York" class="datetime">Dec 7, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-results-open-label-phase-3-study" hreflang="en">Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Study met primary safety endpoint and showed improvements across multiple endpoints, including measures of pancreatic function- -Potential to modify the course of CF in children as young as one year of age- -Results support FDA and EMA filings in the first quarter of 2018- BOSTON --(BUSINESS
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-results-open-label-phase-3-study" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/55764fff-8438-4e2e-acec-bedc511d9863" type="application/pdf" title="VRTX_News_2017_12_7_General_Business.pdf">Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO&#174; (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years</a></span><span class="filesize"> 94.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-11-10T12:30:00Z" timezone="America/New_York" class="datetime">Nov 10, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-orkambir" hreflang="en">Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-orkambir" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8a4dea04-4bf3-40d6-bef0-e48035905e61" type="application/pdf" title="VRTX_News_2017_11_10_General_Business.pdf">Vertex Receives CHMP Positive Opinion for ORKAMBI&#174; (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union</a></span><span class="filesize"> 22.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-11-03T15:00:00Z" timezone="America/New_York" class="datetime">Nov 3, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-presentations-data-north-american-cystic" hreflang="en">Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Data from ongoing extension study of ORKAMBI ® (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO ® (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination demonstrate
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-presentations-data-north-american-cystic" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b3f3d6a1-7d26-43c3-bd65-57b6334eecd2" type="application/pdf" title="VRTX_News_2017_11_3_General_Business.pdf">Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF</a></span><span class="filesize"> 160.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-11-03T14:34:00Z" timezone="America/New_York" class="datetime">Nov 3, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/phase-3-studies-tezacaftorivacaftor-combination-treatment-people" hreflang="en">Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Data showed significant improvements in lung function (ppFEV 1 ) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/phase-3-studies-tezacaftorivacaftor-combination-treatment-people" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b3f3d6a1-7d26-43c3-bd65-57b6334eecd2" type="application/pdf" title="VRTX_News_2017_11_3_General_Business.pdf">Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine</a></span><span class="filesize"> 160.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-11-02T20:01:00Z" timezone="America/New_York" class="datetime">Nov 2, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-7" hreflang="en">Vertex to Present at the Credit Suisse Healthcare Conference on November 7</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET . Management&#039;s remarks will be available live through Vertex&#039;s website at www.vrtx.com
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-7" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/cabffa30-6bae-44c9-9d83-421cb0d900e6" type="application/pdf" title="VRTX_News_2017_11_2_Webcasts.pdf">Vertex to Present at the Credit Suisse Healthcare Conference on November 7</a></span><span class="filesize"> 10.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-11-01T12:30:00Z" timezone="America/New_York" class="datetime">Nov 1, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-750000-program-support-work-next-generation" hreflang="en">Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  The Vertex Research Innovation Award (RIA) Program Will Now Provide up to $10M in Grants Over the Next Five Years to New Postdoctoral and Faculty Researchers from Around the World BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) announced today a new $750,000 program
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-750000-program-support-work-next-generation" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e92102ab-723e-47fd-92b9-f85606a3bda8" type="application/pdf" title="VRTX_News_2017_11_1_General_Business.pdf">Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers</a></span><span class="filesize"> 17.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-10-25T20:01:00Z" timezone="America/New_York" class="datetime">Oct 25, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2017-financial-results" hreflang="en">Vertex Reports Third-Quarter 2017 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Third-quarter 2017 cystic fibrosis product revenues of $550 million , up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion ; increases ORKAMBI revenue guidance to $1.29 to $1.32 billion
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2017-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b92b14e5-9d8c-499c-a584-f2f5e98a4eba" type="application/pdf" title="VRTX_News_2017_10_25_Financial_Results.pdf">Vertex Reports Third-Quarter 2017 Financial Results</a></span><span class="filesize"> 71.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-10-23T12:32:00Z" timezone="America/New_York" class="datetime">Oct 23, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-doubles-scholarship-program-support-academic-and" hreflang="en">Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Now Accepting Applications for the &quot;All in for CF&quot; Scholarship Program Through Jan. 3, 2018 BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-doubles-scholarship-program-support-academic-and" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/83482895-2824-47ea-b7a8-3b53c9518300" type="application/pdf" title="VRTX_News_2017_10_23_General_Business.pdf">Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families</a></span><span class="filesize"> 15.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-10-17T10:15:00Z" timezone="America/New_York" class="datetime">Oct 17, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-10-year-500-million-corporate-giving-commitment" hreflang="en">Vertex Announces 10-Year, $500 Million Corporate Giving Commitment</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-10-year-500-million-corporate-giving-commitment" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/1921cd2e-abf8-453e-b63f-1ac5678047c0" type="application/pdf" title="VRTX_News_2017_10_17_General_Business.pdf">Vertex Announces 10-Year, $500 Million Corporate Giving Commitment</a></span><span class="filesize"> 17.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-10-16T20:01:00Z" timezone="America/New_York" class="datetime">Oct 16, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2017-financial-results-october-25" hreflang="en">Vertex to Announce Third Quarter 2017 Financial Results on October 25</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2017-financial-results-october-25" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/31d17a77-d45d-4121-86a4-3b799f371fdf" type="application/pdf" title="VRTX_News_2017_10_16_Webcasts.pdf">Vertex to Announce Third Quarter 2017 Financial Results on October 25</a></span><span class="filesize"> 11 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-09-21T20:01:00Z" timezone="America/New_York" class="datetime">Sep 21, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-leerink-partners-roundtable-series-september-27" hreflang="en">Vertex to Present at the Leerink Partners Roundtable Series on September 27</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease &amp;amp; Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET Management&#039;s remarks will be available live through
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-leerink-partners-roundtable-series-september-27" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/2bc65f9a-e7b9-490b-9d53-693888e75b58" type="application/pdf" title="VRTX_News_2017_9_21_Webcasts.pdf">Vertex to Present at the Leerink Partners Roundtable Series on September 27</a></span><span class="filesize"> 10.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-09-19T14:50:00Z" timezone="America/New_York" class="datetime">Sep 19, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-2017-north-american" hreflang="en">Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Eleven abstracts from Vertex&#039;s CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-2017-north-american" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/c3141ff5-274f-4d4e-b96d-10322194c50b" type="application/pdf" title="VRTX_News_2017_9_19_General_Business.pdf">Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference</a></span><span class="filesize"> 106.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-09-07T20:01:00Z" timezone="America/New_York" class="datetime">Sep 7, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-11" hreflang="en">Vertex to Present at the Morgan Stanley Healthcare Conference on September 11</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.m. ET . Management&#039;s remarks will be available live through Vertex&#039;s website at www.vrtx.com
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-11" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0be444a5-1db1-4acf-bfe6-f4a6226bd8a4" type="application/pdf" title="VRTX_News_2017_9_7_Webcasts.pdf">Vertex to Present at the Morgan Stanley Healthcare Conference on September 11</a></span><span class="filesize"> 10.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-09-06T12:05:00Z" timezone="America/New_York" class="datetime">Sep 6, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-tom-graney-senior-vice-president-and-chief" hreflang="en">Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-tom-graney-senior-vice-president-and-chief" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/79509d12-b3df-486a-8cd1-f8a76c9e797c" type="application/pdf" title="VRTX_News_2017_9_6_General_Business.pdf">Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer</a></span><span class="filesize"> 12.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-08-24T15:30:00Z" timezone="America/New_York" class="datetime">Aug 24, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-acceptance-its-applications-review" hreflang="en">Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - FDA grants Priority Review of the application and sets action date of February 28, 2018 - -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-acceptance-its-applications-review" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/339d139f-bb60-477d-92a0-38ac7c474127" type="application/pdf" title="VRTX_News_2017_8_24_General_Business.pdf">Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA</a></span><span class="filesize"> 18.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-08-01T12:01:00Z" timezone="America/New_York" class="datetime">Aug 1, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-more-600-people-ages-2-and" hreflang="en">FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO ® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-more-600-people-ages-2-and" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8a0f411a-8b16-47da-8f85-d0dafede3492" type="application/pdf" title="VRTX_News_2017_8_1_General_Business.pdf">FDA Approves KALYDECO&#174; (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations</a></span><span class="filesize"> 24.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-26T20:01:00Z" timezone="America/New_York" class="datetime">Jul 26, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2017-financial-results" hreflang="en">Vertex Reports Second-Quarter 2017 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Second-quarter 2017 cystic fibrosis product revenues of $514 million ; $324 million for ORKAMBI and $190 million for KALYDECO- -Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&amp;amp;D and SG&amp;amp;A expenses- -Pipeline of
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2017-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8870f7e2-3482-4295-bd1c-798b065b4d3d" type="application/pdf" title="VRTX_News_2017_7_26_Financial.pdf">Vertex Reports Second-Quarter 2017 Financial Results</a></span><span class="filesize"> 57.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-25T20:01:00Z" timezone="America/New_York" class="datetime">Jul 25, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-concert-pharmaceuticals-complete-asset-purchase" hreflang="en">Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON &amp;amp; LEXINGTON, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-concert-pharmaceuticals-complete-asset-purchase" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/e6b13e61-478e-41f5-a38e-b248f60a0c19" type="application/pdf" title="VRTX_News_2017_7_25_General_Business.pdf">Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656</a></span><span class="filesize"> 20.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-18T20:01:00Z" timezone="America/New_York" class="datetime">Jul 18, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-phase-1-phase-2-data-three-different" hreflang="en">Vertex Announces Positive Phase 1 &amp; Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Phase 2 data showed mean absolute improvements in ppFEV 1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients; Initial data from Phase 1 study showed mean absolute improvement in ppFEV 1 of 9.6
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-phase-1-phase-2-data-three-different" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a62a13f4-cbee-47b9-8c41-bf049c85a15d" type="application/pdf" title="VRTX_News_2017_7_18_General_Business.pdf">Vertex Announces Positive Phase 1 &amp; Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)</a></span><span class="filesize"> 40.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-17T12:45:00Z" timezone="America/New_York" class="datetime">Jul 17, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-awards-two-first-generation-college-students-full" hreflang="en">Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Boston Public High School Students Hannah Mei and Sayed Shah Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at UMass BOSTON --(BUSINESS WIRE)-- Vertex , Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-awards-two-first-generation-college-students-full" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/41238a51-be6f-4676-a1f4-c148a101e9cb" type="application/pdf" title="VRTX_News_2017_7_17_General_Business.pdf">Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts</a></span><span class="filesize"> 21.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-13T12:00:00Z" timezone="America/New_York" class="datetime">Jul 13, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2017-financial-results-july-26" hreflang="en">Vertex to Announce Second Quarter 2017 Financial Results on July 26</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close. The company will host a conference call and webcast at 5:15 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2017-financial-results-july-26" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5cd8ae0a-0f1f-42d8-bda3-c8a59ac0f952" type="application/pdf" title="VRTX_News_2017_7_13_Webcasts.pdf">Vertex to Announce Second Quarter 2017 Financial Results on July 26</a></span><span class="filesize"> 10.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-07-13T08:00:00Z" timezone="America/New_York" class="datetime">Jul 13, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-reimbursement-agreement-italy-orkambir" hreflang="en">Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of other
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-reimbursement-agreement-italy-orkambir" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a53c4172-bdc3-49f1-8389-cc2a28fa8ae1" type="application/pdf" title="VRTX_News_2017_7_13_General_Business.pdf">Vertex Announces Reimbursement Agreement in Italy for ORKAMBI&#174; (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation</a></span><span class="filesize"> 19.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-06-09T12:30:00Z" timezone="America/New_York" class="datetime">Jun 9, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13" hreflang="en">Vertex to Present at the Goldman Sachs Healthcare Conference on June 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.m. ET . Management&#039;s remarks will be available live through Vertex&#039;s website at www.vrtx.com in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/408a54b4-8c78-42d3-a544-514da4834a6c" type="application/pdf" title="VRTX_News_2017_6_9_Webcasts.pdf">Vertex to Present at the Goldman Sachs Healthcare Conference on June 13</a></span><span class="filesize"> 10.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-06-09T08:31:00Z" timezone="America/New_York" class="datetime">Jun 9, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-nine-presentations-data-orkambir" hreflang="en">Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-nine-presentations-data-orkambir" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5785623e-ce25-4483-90ed-57544c4ef345" type="application/pdf" title="VRTX_News_2017_6_9_General_Business.pdf">Vertex Announces Nine Presentations of Data on ORKAMBI&#174; (lumacaftor/ivacaftor) and KALYDECO&#174; (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference</a></span><span class="filesize"> 29.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2017-06-08T20:15:00Z" timezone="America/New_York" class="datetime">Jun 8, 2017</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-names-dr-alan-garber-provost-harvard-university-its-board" hreflang="en">Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today elected Alan M. Garber , M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University , the Mallinckrodt Professor of Health Care Policy at Harvard
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-names-dr-alan-garber-provost-harvard-university-its-board" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/08037e70-4b9a-4c97-ba6b-a3c55e7240f6" type="application/pdf" title="VRTX_News_2017_6_8_General_Business.pdf">Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors</a></span><span class="filesize"> 16.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=5" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=5" title="Go to page 6">
            <span class="visually-hidden">
              Page
            </span>6</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=6" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>7</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=7" title="Go to page 8">
            <span class="visually-hidden">
              Page
            </span>8</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=8" title="Go to page 9">
            <span class="visually-hidden">
              Page
            </span>9</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=7" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 301 - 350 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"6"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
